A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response-Reference-Cited by-同舟云学术

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Published:2023-04-24 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Rubio-Pérez Laura¹²³⁴^ORCID,Lázaro-Gorines Rodrigo¹²³^ORCID,Harwood Seandean L.⁵^ORCID,Compte Marta⁶^ORCID,Navarro Rocío⁶^ORCID,Tapia-Galisteo Antonio¹²³^ORCID,Bonet Jaume⁷^ORCID,Blanco Belén¹²³^ORCID,Lykkemark Simon⁸^ORCID,Ramírez-Fernández Ángel¹²³^ORCID,Ferreras-Gutiérrez Mariola⁹^ORCID,Domínguez-Alonso Carmen¹²³^ORCID,Díez-Alonso Laura¹²³^ORCID,Segura-Tudela Alejandro¹²³^ORCID,Hangiu Oana¹²⁶,Erce-Llamazares Ainhoa¹²⁶,Blanco Francisco J.⁹^ORCID,Santos Cruz¹⁰^ORCID,Rodríguez-Peralto José L.¹¹¹²¹³¹⁴^ORCID,Sanz Laura¹⁴¹⁵^ORCID,Álvarez-Vallina Luis¹²³⁴^ORCID

Affiliation:

1. Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain

2. Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain

3. H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

4. Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV), Madrid, Spain

5. Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark

6. Department of Antibody Engineering, Leadartis SL, QUBE Technology Park, Madrid, Spain

7. Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

8. Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, Aarhus C, Denmark

9. Centro de Investigaciones Biológicas Margarita Salas (CIB), CSIC, Madrid, Spain

10. Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain

11. Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain

12. Department of Pathology, Universidad Complutense, Madrid, Spain

13. Cutaneous Oncology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain

14. Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spain

15. Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2205336

Reference47 articles.

1. Combination cancer immunotherapy and new immunomodulatory targets

2. The diverse functions of the PD1 inhibitory pathway

3. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

4. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

5. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates;Toxicology and Applied Pharmacology;2024-06

2. Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1;Antibodies;2024-05-02

3. Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity;Antibodies;2024-04-24

4. Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1;Antibodies;2024-02-20

5. Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG12-KL4 peptide to the lungs as potential strategy against non-small cell lung cancer;European Journal of Pharmaceutics and Biopharmaceutics;2024-02